Search - tctmd.com

Displaying 41 - 60 of 380

Sort: Relevancy | Date

Presentation TCT 2024

TCT 237: Long-Term Clopidogrel vs Aspirin Monotherapy in Stable Coronary Artery Disease Patients With High Ischemic Risk: A Post Hoc Analysis of the HOST-EXAM Extended Study

Presenter: Jeehoon Kang

October 27, 2024

Presentation TCT 2024

TCT 236: Bailout Use of Cangrelor During Percutaneous Coronary Intervention and Associated Inpatient Outcomes

Presenter: Abhishek Chaturvedi

October 27, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2024

Shelley Wood

October 01, 2024

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

News Conference News ESC 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

Yael L. Maxwell

September 10, 2024

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

Todd Neale

September 01, 2024

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

News Daily News

Ideal Aspirin Dose in Secondary Prevention Doesn’t Differ Much by Sex

Caitlin E. Cox

July 11, 2024

Presentation EuroPCR 2024

Site-specific antithrombotic therapy: DESyne BDS Plus study 12-month outcomes

Presenter: Alexandre Abizaid

May 14, 2024

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

Presentation TCT 2023

Where Do Antithrombotics Fit In?

Presenter: Marc Bonaca

October 26, 2023

Presentation TCT 2023

Optimal Antithrombotic Strategies in MCS Use

Presenter: Mirvat Alasnag

October 26, 2023

Presentation TCT 2023

TCT 406: Effect of Antithrombotic Strategies on Total Outcome Events in Patients with Atrial Fibrillation after Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights from AUGUSTUS

Presenter: Manasi Tannu

October 26, 2023

Presentation TCT 2023

Case Resolution: Long-term Therapy

Presenter: NULL

October 25, 2023

Presentation TCT 2023

The Guidelines Need Updating: 3-6 Months of DAPT Is Sufficient

Presenter: John Bittl

October 25, 2023

Presentation TCT 2023

Longer Term DAPT Is What The Guidelines and Data Support

Presenter: Mamas Mamas

October 25, 2023

Presentation TCT 2023

Case Continuation: In Hospital Management

Presenter: Davide Cao

October 25, 2023

Presentation TCT 2023

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Presenter: Michael Savage

October 25, 2023

Presentation TCT 2023

Cangrelor Reduces Procedural Complications and Should Be the Default Strategy

Presenter: Jennifer Rymer

October 25, 2023

Advertisement

TCT 237: Long-Term Clopidogrel vs Aspirin Monotherapy in Stable Coronary Artery Disease Patients With High Ischemic Risk: A Post Hoc Analysis of the HOST-EXAM Extended Study

TCT 236: Bailout Use of Cangrelor During Percutaneous Coronary Intervention and Associated Inpatient Outcomes

TCTMD’s Top 10 Most Popular Stories for September 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Ideal Aspirin Dose in Secondary Prevention Doesn’t Differ Much by Sex

Site-specific antithrombotic therapy: DESyne BDS Plus study 12-month outcomes

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Where Do Antithrombotics Fit In?

Optimal Antithrombotic Strategies in MCS Use

TCT 406: Effect of Antithrombotic Strategies on Total Outcome Events in Patients with Atrial Fibrillation after Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights from AUGUSTUS

Case Resolution: Long-term Therapy

The Guidelines Need Updating: 3-6 Months of DAPT Is Sufficient

Longer Term DAPT Is What The Guidelines and Data Support

Case Continuation: In Hospital Management

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Cangrelor Reduces Procedural Complications and Should Be the Default Strategy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content